Study, with all due respect, we were not at $1.30-$1.40. We were below $1.20 until Denner announced proxy fight. We haven’t earned a dime in EU as far as I can tell. We failed in Germany and were delayed just about everywhere else. Generics were, and still are, eroding scripts and AMRN BOD was signaling they’re giving up on fighting for the US market. Generics have more access to API and will take more scripts this year. AMRN expects losses this year so 1 quarter of profit was all we were getting. Given all these issues, AMRN should have launched a branded or authorized generic already for the Marine indication while continuing to sell brand V for CVD. If we did, we could have worked through API inventory and possibly maintained our supply commitments. The settlement is a secret and we were told it’s beneficial to AMRN. I don’t see it yet. Lastly, we all were completely ignored by management while these issues were not fully addressed. AMRN basically asked us to just trust them while scripts and stock prices plummeted. Meanwhile they bought virtually zero shares. We were flying blind through one failure after the next. AMRN management/BOD left us no choice.They could have added two Sarissa reps but chose not too. I don’t regret my decision one bit at this point. We have a team with 25 million shares fighting for us now. Hope this helps you feel better. Haha.
News 
Market Data 
Discover 
AI
